MacroGenics Inc

MacroGenics Inc. a biopharmaceutical company develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb) a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated in combination with chemotherapy for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018 an antibody drug conjugate (ADC) which targets solid tumors expressing B7-H3; Enoblituzumab a monoclonal antibody that targets B7-H3; and MGD024 an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition it develops Lorigerlimab a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab an monoclonal antibody used for cancer therapeutics; and IMGC936 an ADC that targets ADAM9 a cell surface protein over-expressed in various solid tumor types. Further the company develops MGD014 and MGD020 a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279 a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech Inc. The company was incorporated in 2000 and is headquartered in Rockville Maryland.